Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pharmacokinetic analysis of an extended-pulsed fidaxomicin regimen for the treatment of Clostridioides (Clostridium) difficile infection in patients aged 60 years and older in the EXTEND randomized controlled trial.
Guery B, Georgopali A, Karas A, Kazeem G, Michon I, Wilcox MH, Cornely OA. Guery B, et al. Among authors: kazeem g. J Antimicrob Chemother. 2020 Apr 1;75(4):1014-1018. doi: 10.1093/jac/dkz549. J Antimicrob Chemother. 2020. PMID: 31960058 Free article. Clinical Trial.
Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial.
Guery B, Menichetti F, Anttila VJ, Adomakoh N, Aguado JM, Bisnauthsing K, Georgopali A, Goldenberg SD, Karas A, Kazeem G, Longshaw C, Palacios-Fabrega JA, Cornely OA, Vehreschild MJGT; EXTEND Clinical Study Group. Guery B, et al. Among authors: kazeem g. Lancet Infect Dis. 2018 Mar;18(3):296-307. doi: 10.1016/S1473-3099(17)30751-X. Epub 2017 Dec 19. Lancet Infect Dis. 2018. PMID: 29273269 Clinical Trial.
Microbiological Characterization and Clinical Outcomes After Extended-Pulsed Fidaxomicin Treatment for Clostridioides difficile Infection in the EXTEND Study.
Wilcox MH, Cornely OA, Guery B, Longshaw C, Georgopali A, Karas A, Kazeem G, Palacios-Fabrega JA, Vehreschild MJGT. Wilcox MH, et al. Among authors: kazeem g. Open Forum Infect Dis. 2019 Nov 6;6(11):ofz436. doi: 10.1093/ofid/ofz436. eCollection 2019 Nov. Open Forum Infect Dis. 2019. PMID: 31723569 Free PMC article.
Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
Mourad G, Glyda M, Albano L, Viklický O, Merville P, Tydén G, Mourad M, Lõhmus A, Witzke O, Christiaans MHL, Brown MW, Undre N, Kazeem G, Kuypers DRJ; Advagraf-based immunosuppression regimen examining new onset diabetes mellitus in kidney transplant recipients (ADVANCE) study investigators. Mourad G, et al. Among authors: kazeem g. Transplantation. 2017 Aug;101(8):1924-1934. doi: 10.1097/TP.0000000000001453. Transplantation. 2017. PMID: 27547871 Free PMC article. Clinical Trial.
Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate- or prolonged-release tacrolimus.
Vondrak K, Parisi F, Dhawan A, Grenda R, Webb NJA, Marks SD, Debray D, Holt RCL, Lachaux A, Kelly D, Kazeem G, Undre N. Vondrak K, et al. Among authors: kazeem g. Clin Transplant. 2019 Oct;33(10):e13698. doi: 10.1111/ctr.13698. Epub 2019 Sep 19. Clin Transplant. 2019. PMID: 31436896 Free PMC article. Clinical Trial.
Efficacy and safety of prolonged-release tacrolimus in stable pediatric allograft recipients converted from immediate-release tacrolimus - a Phase 2, open-label, single-arm, one-way crossover study.
Rubik J, Debray D, Kelly D, Iserin F, Webb NJA, Czubkowski P, Vondrak K, Sellier-Leclerc AL, Rivet C, Riva S, Tönshoff B, D'Antiga L, Marks SD, Reding R, Kazeem G, Undre N. Rubik J, et al. Among authors: kazeem g. Transpl Int. 2019 Nov;32(11):1182-1193. doi: 10.1111/tri.13479. Epub 2019 Aug 27. Transpl Int. 2019. PMID: 31325368 Free PMC article. Clinical Trial.
Long-term, prolonged-release tacrolimus-based immunosuppression in de novo kidney transplant recipients: 5-year prospective follow-up of the ADHERE study patients.
Rummo O, Carmellini M, Kamar N, Durrbach A, Mousson C, Caputo F, Mathe Z, Christiaans MHL, Kuypers DRJ, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Lehner F. Rummo O, et al. Among authors: kazeem g. Transpl Int. 2020 Feb;33(2):161-173. doi: 10.1111/tri.13527. Epub 2019 Oct 24. Transpl Int. 2020. PMID: 31536654 Free article. Clinical Trial.
Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study.
Friman S, Tisone G, Nevens F, Lehner F, Santaniello W, Bechstein WO, Zhuvarel SV, Isoniemi H, Rummo OO, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Trunečka P. Friman S, et al. Among authors: kazeem g. Transplant Direct. 2021 Jul 9;7(8):e722. doi: 10.1097/TXD.0000000000001166. eCollection 2021 Aug. Transplant Direct. 2021. PMID: 34263020 Free PMC article.
A randomised phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer.
Dittrich C, Papai-Szekely Z, Vinolas N, Sederholm C, Hartmann JT, Behringer D, Kazeem G, Desaiah D, Leschinger MI, von Pawel J. Dittrich C, et al. Among authors: kazeem g. Eur J Cancer. 2014 Jun;50(9):1571-80. doi: 10.1016/j.ejca.2014.03.007. Epub 2014 Apr 2. Eur J Cancer. 2014. PMID: 24703574 Clinical Trial.
28 results